154 related articles for article (PubMed ID: 17400380)
1. Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification.
Yamamori H; Khatoon S; Grundke-Iqbal I; Blennow K; Ewers M; Hampel H; Iqbal K
Neurosci Lett; 2007 May; 418(2):186-9. PubMed ID: 17400380
[TBL] [Abstract][Full Text] [Related]
2. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
3. Gold nanoparticle-based immuno-PCR for detection of tau protein in cerebrospinal fluid.
Stegurová L; Dráberová E; Bartos A; Dráber P; Rípová D; Dráber P
J Immunol Methods; 2014 Apr; 406():137-42. PubMed ID: 24642424
[TBL] [Abstract][Full Text] [Related]
4. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.
Kohnken R; Buerger K; Zinkowski R; Miller C; Kerkman D; DeBernardis J; Shen J; Möller HJ; Davies P; Hampel H
Neurosci Lett; 2000 Jun; 287(3):187-90. PubMed ID: 10863026
[TBL] [Abstract][Full Text] [Related]
5. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
Blennow K; Wallin A; Agren H; Spenger C; Siegfried J; Vanmechelen E
Mol Chem Neuropathol; 1995 Dec; 26(3):231-45. PubMed ID: 8748926
[TBL] [Abstract][Full Text] [Related]
6. Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.
Lewczuk P; Lelental N; Lachmann I; Holzer M; Flach K; Brandner S; Engelborghs S; Teunissen CE; Zetterberg H; Molinuevo JL; Mroczko B; Blennow K; Popp J; Parnetti L; Chiasserini D; Perret-Liaudet A; Spitzer P; Maler JM; Kornhuber J
J Alzheimers Dis; 2017; 55(1):159-170. PubMed ID: 27662295
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
8. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
9. Increased cerebrospinal fluid tau in patients with Alzheimer's disease.
Jensen M; Basun H; Lannfelt L
Neurosci Lett; 1995 Feb; 186(2-3):189-91. PubMed ID: 7777193
[TBL] [Abstract][Full Text] [Related]
10. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
12. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.
Vandermeeren M; Mercken M; Vanmechelen E; Six J; van de Voorde A; Martin JJ; Cras P
J Neurochem; 1993 Nov; 61(5):1828-34. PubMed ID: 8228996
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
Hu Y; He S; Wang J
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
[TBL] [Abstract][Full Text] [Related]
15. Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.
Lachno DR; Romeo MJ; Siemers ER; Vanderstichele H; Coart E; Konrad RJ; Zajac JJ; Talbot JA; Jensen HF; Sethuraman G; Demattos RB; May PC; Dean RA
J Alzheimers Dis; 2011; 26(3):531-41. PubMed ID: 21694458
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
[TBL] [Abstract][Full Text] [Related]
17. [Tau protein in cerebrospinal fluid--a potential marker of Alzheimer's disease].
Arai H; Satoh K; Terajima M; Nakagawa T; Higuchi M; Kosaka Y; Zhu C; Sasaki H
Nihon Ronen Igakkai Zasshi; 1996 Sep; 33(9):669-75. PubMed ID: 8940864
[TBL] [Abstract][Full Text] [Related]
18. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
[TBL] [Abstract][Full Text] [Related]
19. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
[TBL] [Abstract][Full Text] [Related]
20. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls.
Struyfs H; Molinuevo JL; Martin JJ; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2014; 41(3):903-9. PubMed ID: 24705548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
